Incremental diagnostic value of Florbetaben Imaging vs other core biomarkers for Alzheimer Disease in patients with Mild Cognitive Impairment. An Investigator-Initiated Sponsored Study. Valore diagnostico incrementale di Florbetaben Imaging vs altri biomarcatori chiave per la Malattia di Alzheimer in pazienti con Deterioramento

Trial Profile

Incremental diagnostic value of Florbetaben Imaging vs other core biomarkers for Alzheimer Disease in patients with Mild Cognitive Impairment. An Investigator-Initiated Sponsored Study. Valore diagnostico incrementale di Florbetaben Imaging vs altri biomarcatori chiave per la Malattia di Alzheimer in pazienti con Deterioramento

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Feb 2018

At a glance

  • Drugs Florbetaben F18 (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Diagnostic use
  • Most Recent Events

    • 23 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top